Article Details
Retrieved on: 2018-05-08 06:40:33
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div><b>Benchmark Capital</b> Advisors increased its position in Galectin Therapeutics by 19.7% during the first quarter. <b>Benchmark Capital</b> Advisors now owns ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here